Fasting and Cancer: What the Science Says

1. What do researchers mean by fasting?

In cancer research, “fasting” can mean several different things. Short-term fasting usually means taking in no calories for 24 to 72 hours, often around chemotherapy. Intermittent fasting may mean eating within a set daily window or having a longer overnight fast. Calorie restriction means eating fewer calories over a longer period while trying to avoid malnutrition. A fasting-mimicking diet, or FMD, is a low-calorie, low-protein, plant-based diet designed to create some fasting-like metabolic changes while still allowing small amounts of food.

Those differences are not minor details. A 13-hour overnight fast after dinner is very different from a 60-hour fast around chemotherapy. A five-day FMD is different again. When studies are small and use different fasting plans, it becomes hard to pool the results or give one simple answer.

2. How fasting might affect cancer biology

The basic idea is that fasting changes the nutrient signals that tell cells whether energy is abundant or scarce. After a period without food, blood glucose and insulin usually fall. Levels of IGF-1, a growth-related hormone, may also fall in some settings. These shifts can quiet growth pathways such as AKT-mTOR, which many cancer cells use to keep dividing.

Researchers also focus on metabolic stress. Many cancer cells rely heavily on glucose fermentation, often called the Warburg effect. When nutrients are limited, normal cells can often slow down and protect themselves. Cancer cells may be less adaptable, especially when chemotherapy or targeted therapy is added. This is the basis of two related ideas: differential stress resistance, where normal cells become more resistant to treatment stress, and differential stress sensitization, where cancer cells become more vulnerable.

Other possible mechanisms include autophagy, the cell’s recycling system; changes in oxidative stress; lower leptin and inflammatory signals; and immune remodeling. In early human FMD studies, researchers have seen immune-cell shifts that look less suppressive and more anti-tumor. These signals are interesting, but they are not the same as proving that people live longer.

3. Fasting and cancer prevention: promising biology, weak human proof

Cancer prevention is the harder question to answer. In rodents, calorie restriction, intermittent fasting and fasting-mimicking diets can delay or reduce cancer development. That has made the insulin and IGF-1 pathway a major focus. Lower growth signaling is one reason these approaches look protective in animals.

Human evidence is less tidy. In a trial of 100 generally healthy adults, three monthly cycles of a five-day FMD reduced body weight, body fat, blood pressure and IGF-1, especially in people with less favorable baseline markers. That is prevention-adjacent evidence: it shows changes in risk markers, not fewer cancers.

Longer calorie restriction studies add a note of caution. In the CALERIE trial, two years of calorie restriction in non-obese adults changed some IGF-binding markers but did not clearly lower total IGF-1. Another human study found that long-term severe calorie restriction without malnutrition did not lower IGF-1, while moderate protein restriction did. So the idea that simply eating fewer calories reliably lowers IGF-1 in humans is too simple.

There is also observational evidence. In women previously treated for early-stage breast cancer, fasting less than 13 hours overnight was associated with a higher risk of recurrence, but not clearly with breast-cancer-specific or overall mortality. This is suggestive, not causal. People who fast longer overnight may also differ in sleep, meal timing, body weight, diabetes risk and other behaviors.

The honest prevention answer is this: fasting can improve some metabolic markers linked to cancer risk, but no randomized human trial has shown that fasting or FMDs prevent cancer.

4. Fasting during cancer treatment: what human trials show

Treatment studies are further along than prevention studies, but they are still early. The strongest signals come from breast cancer trials using FMDs during chemotherapy.

In the phase II DIRECT trial, 131 patients with HER2-negative stage II or III breast cancer were assigned to an FMD or a regular diet around neoadjuvant chemotherapy. Overall toxicity did not differ, even though the FMD group omitted dexamethasone. Radiologic response was more common in the FMD group, and among patients who followed the protocol, a stronger pathologic response was also more likely. The study also found less chemotherapy-related DNA damage in T-lymphocytes, a type of immune cell. These are encouraging findings, but the trial was not designed to give a definitive answer on survival.

A more recent small randomized trial in 44 HER2-negative breast cancer patients also reported lower IGF-1 and inflammation, less severe vomiting and neutropenia, and better short-term response measures with FMD during neoadjuvant chemotherapy. Again, there were no survival data.

Other studies are smaller and more mixed. In gynecologic cancers, a pilot study of 48-hour water-only fasting found it was generally well tolerated and was associated with fewer chemotherapy dose delays or reductions. A randomized cross-over study in breast and ovarian cancer suggested less fatigue and less quality-of-life decline during fasted chemotherapy cycles. Another pilot study of modified 96-hour fasting lowered insulin and IGF-1 and suggested fewer toxicities.

A phase I study of cyclic five-day FMDs in 101 patients with different cancers found the approach feasible in selected patients and showed lower glucose and growth factors, along with immune changes that could be favorable. A separate phase I-II trial in 90 patients at low nutritional risk found mostly mild side effects, stable weight and handgrip strength, and favorable shifts in body composition and metabolic markers.

Systematic reviews pull the conclusion back to earth. Reviews of the clinical literature find that fasting is often feasible in carefully chosen patients, but the studies are small, varied and mostly focused on breast or gynecologic cancers. The most current synthesis found no clear overall effect on treatment outcomes or chemotherapy toxicity, even though insulin and IGF-1 often fell.

So far, there is no high-quality evidence that fasting improves progression-free survival or overall survival in cancer patients.

5. Safety: when fasting may be the wrong idea

Cancer care is not a typical wellness setting. Many patients deal with appetite loss, nausea, mouth sores, diarrhea, taste changes, bowel obstruction or fatigue. Some lose weight before treatment even starts. Others develop sarcopenia, which means low muscle mass, or cachexia, a wasting syndrome that can involve weight loss, inflammation and muscle breakdown.

In those situations, fasting may make things worse. Poor nutrition can reduce treatment tolerance, slow recovery, increase infection risk and make fatigue harder to manage. Official nutrition guidance in cancer care emphasizes screening for malnutrition and treating inadequate intake early. For some patients, the priority is not fasting; it is getting enough protein, calories and fluids to stay strong enough for therapy.

The safety data from FMD trials mostly apply to people who were well nourished, carefully screened and monitored. Some protocols shortened or stopped fasting if body composition or nutritional markers worsened. That is very different from trying a prolonged fast alone during active treatment.

Anyone considering fasting during cancer care should ask three questions: Am I losing weight without trying? Am I eating less because of treatment side effects? Have I lost strength or muscle? If the answer is yes, fasting is likely to carry more risk and needs medical guidance.